The third stage of the research with Soberana 02, developed by the Finlay Institute of Vaccines (IFV) in Havana, is designed in periods of zero, 28 and 56 days with 44,010 sample of volunteers, divided into three groups.

The first group receives two doses of Soberana 02, the second group gets two doses plus a third immune booster with Soberana Plus and the third receives a placebo, a compound devoid of the active substances. IFV researchers confirmed the safety and immunogenicity of the vaccine candidate and at this stage, they are assessing the efficacy of the formulation in the symptomatic and severe disease, as well as in contagion and transmission.

Havana, the capital, is the epicenter of the disease, hence, along with the clinical trial, health authorities and the scientific community decided to extend vaccination to risk groups and territories at first with Abdala (CIGB-66), the second anti-Covid-19 vaccine candidate that is also being tested as a future vaccine.

To date, more than 2,700,000 people have received at least one dose of the vaccine candidates in intervention studies and health interventions.

ef/iff/jf/alb